openPR Logo
Press release

Bioquark Inc. and Revita Life Sciences Receive IRB Approval for First-In-Human Brain Death Study

04-25-2016 11:46 AM CET | Health & Medicine

Press release from: Bioquark Inc.

Bioquark Inc. and Revita Life Sciences Receive IRB Approval

Bioquark, Inc., (http://www.bioquark.com) a company focused on the development of novel biologics for complex regeneration and disease reversion, and Revita Life Sciences, (http://revitalife.co.in) a biotechnology company focused on translational therapeutic applications of autologous stem cells, have announced that they have received IRB approval for a study focusing on a novel combinatorial approach to clinical intervention in the state of brain death in humans.

This first trial, within the portfolio of Bioquark's Reanima Project (http://www.reanima.tech) is entitled “Non-randomized, Open-labeled, Interventional, Single Group, Proof of Concept Study With Multi-modality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury” (https://clinicaltrials.gov/ct2/show/NCT02742857?term=bioquark&rank=1), will enroll an initial 20 subjects, and be conducted at Anupam Hospital in Rudrapur, Uttarakhand India.

“We are very excited about the approval of our protocol,” said Ira S. Pastor, CEO, Bioquark Inc. “With the convergence of the disciplines of regenerative biology, cognitive neuroscience, and clinical resuscitation, we are poised to delve into an area of scientific understanding previously inaccessible with existing technologies.”

Death is defined as the termination of all biological functions that sustain a living organism. Brain death, the complete and irreversible loss of brain function (including involuntary activity necessary to sustain life) as defined in the 1968 report of the Ad Hoc Committee of the Harvard Medical School, is the legal definition of human death in most countries around the world. Either directly through trauma, or indirectly through secondary disease indications, brain death is the final pathological state that over 60 million people globally transfer through each year.

While human beings lack substantial regenerative capabilities in the CNS, many non-human species, such as amphibians, planarians, and certain fish, can repair, regenerate and remodel substantial portions of their brain and brain stem even after critical life-threatening trauma.

Additionally, recent studies on complex brain regeneration in these organisms, have highlighted unique findings in relation to the storage of memories following destruction of the entire brain, which may have wide ranging implications for our understanding of consciousness and the stability of memory persistence.

“Through our study, we will gain unique insights into the state of human brain death, which will have important connections to future therapeutic development for other severe disorders of consciousness, such as coma, and the vegetative and minimally conscious states, as well as a range of degenerative CNS conditions, including Alzheimer's and Parkinson's disease,” said Dr. Sergei Paylian, Founder, President, and Chief Science Officer of Bioquark Inc.

Over the years, clinical science has focused heavily on preventing such life and death transitions and made some initial progress with suspended animation technologies, such as therapeutic hypothermia. However, once humans transition through the brain death window, currently defined by the medical establishment as “irreversible”, they are technically no longer alive, despite the fact that human bodies can still circulate blood, digest food, excrete waste, balance hormones, grow, sexually mature, heal wounds, spike a fever, and gestate and deliver a baby. It is even acknowledged by thought leaders that recently brain dead humans still may have residual blood flow and electrical nests of activity in their brains, just not enough to allow for an integrated functioning of the organism as a whole.

“We look forward to working closely with Bioquark Inc. on this cutting edge clinical initiative,” said Dr. Himanshu Bansal, Managing Director of Revita Life Sciences.

About Bioquark, Inc.

Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.

About Revita Life Sciences

Revita Life Sciences is a biotechnology company focused on the development of stem cell therapies that target areas of significant unmet medical need. Revita is led by Dr. Himanshu Bansal MD, PhD. who has spent over two decades developing novel MRI based classifications of spinal cord injuries as well as comprehensive treatment protocols with autologous tissues including bone marrow stem cells, dural nerve grafts, nasal olfactory tissues, and omental transposition.

Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.

1735 Market Street
Suite 3750
Phila, PA 19103
USA

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bioquark Inc. and Revita Life Sciences Receive IRB Approval for First-In-Human Brain Death Study here

News-ID: 335183 • Views:

More Releases from Bioquark Inc.

Bioquark Inc. and Ectocrine Technologies LLC to Collaborate on Mosquito-Derived …
Bioquark, Inc., an innovative life sciences company focused biotherapeutic development for human regeneration and disease reversion, and Ectocrine Technologies LLC, a biotech company dedicated to studying the positive human physiological effects of salivary secretions of hematophagous arthropods, such as mosquitos, of have announced a collaboration to focus on developing novel bio-products for human health and wellness. "We are very excited about this collaboration with Ectocrine Technologies," said Ira S. Pastor, CEO,

More Releases for Revita

Europe Iv Hydration Therapy Market is evolving rapidly Through 2025 To 2032 | RE …
Coherent Market Insights Reports has released a detailed research analysis on the "Europe Iv Hydration Therapy Market 2025", highlighting key trends, growth dynamics, and forecast insights through 2032. This comprehensive report presents an in-depth evaluation of the market landscape, analyzing the factors that influence industry growth, including manufacturers, suppliers, market participants, and end users. It offers valuable insights into the core drivers fueling market expansion across various segments such as
Europe Iv Hydration Therapy Market Exclusive Report with Detailed Study Analysis …
The Europe Iv Hydration Therapy Market Research Report is the result of extensive research and analysis conducted by our team of experienced market researchers. It encompasses a wide range of critical factors influencing the Europe Iv Hydration Therapy Market Growth from 2025 to 2032, including competitive landscape, consumer behavior, and technological advancements. This report serves as a valuable resource for industry players, helping them make informed decisions and stay ahead
Europe Iv Hydration Therapy Market Generated Opportunities, Future Scope 2025-20 …
The qualitative latest Research report (2025-2032) on the Europe Iv Hydration Therapy Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves. Request a Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/5021 Focused on
Europe IV Hydration Therapy Market to Witness Substantial Growth | Key Drivers & …
The Global Europe Iv Hydration Therapy Market is expected to grow at 7.2% CAGR from 2025 to 2032. The latest Research report published by CMI with the title "An Increase in Demand and Opportunities for Global Europe Iv Hydration Therapy Market 2025" provides a sorted image of the Europe Iv Hydration Therapy Market industry by analysis of research and information collected from various sources that have the ability to help the
Europe Iv Hydration Therapy Market Overall Study Report 2024-2031 | REVITA, Ivth …
Europe Iv Hydration Therapy Market Trends Overview 2024-2031: A new Report by Coherent Market Insights, titled "Europe Iv Hydration Therapy Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the Europe Iv Hydration Therapy market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. This report has a complete table of contents, figures, tables,
REVITA BEAUTY REVIEW 2023: BUYERS BEWARE! HOW LEGIT IS REVITA BEAUTY?
In a world where the pursuit of eternal youth has fueled a thriving beauty industry, a game-changing innovation has emerged, promising a transformative approach to achieving radiant, youthful skin. Say hello to the Revita Beauty 5-In-1 Skin Therapy Wand, a revolutionary device that challenges conventional beauty norms and empowers individuals to take control of their skincare journey. Gone are the days of investing exorbitant amounts in overhyped luxury brand creams and